MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

医学 耐受性 内科学 养生 细胞因子释放综合征 耐火材料(行星科学) 来那度胺 中性粒细胞减少症 多发性骨髓瘤 不利影响 肿瘤科 外科 毒性 免疫疗法 嵌合抗原受体 癌症 物理 天体生物学
作者
Jeffrey A. Zonder,Joshua Richter,Naresh Bumma,Jason Brayer,James E. Hoffman,William Bensinger,Ka Lung Wu,Linzhi Xu,Dhruti Chokshi,Anita Boyapati,Damien M. Cronier,Yariv Houvras,Karen Rodriguez Lorenc,Glenn S. Kroog,Madhav V. Dhodapkar,Suzanne Lentzsch,Dennis Cooper,Sundar Jagannath
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:22: S406-S407 被引量:3
标识
DOI:10.1016/s2152-2650(22)01591-9
摘要

Despite advances in treatment options, multiple myeloma remains incurable. REGN5458 is a BCMAxCD3 bispecific antibody under investigation in relapsed/refractory multiple myeloma (RRMM): ongoing Phase 1/2 trial (NCT03761108).To describe updated safety, overall response, and response durability in patients treated with REGN5458 in the Phase 1 part.The Phase 1 part follows a modified 3+3 dose-escalation design (4+3).Eligible patients with progressive RRMM, who were double- or triple-refractory, or intolerant to prior lines of systemic therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody, were included.Sixteen weekly infusions of REGN5458 monotherapy, then every two weeks until disease progression.Primary objectives were to assess safety, tolerability, and occurrence of dose-limiting toxicities of REGN5458, and to determine a recommended Phase 2 dose regimen. The objective response rate by modified International Myeloma Working Group criteria was a key secondary objective.At data cut-off (September 30, 2021), 73 patients were treated with REGN5458 in the dose-escalation cohort, with full doses ranging from 3-800 mg. The median age at enrollment was 64 years (range, 41-81). As per the Revised International Staging System, stages were 1, 2, or 3 in 15.0%, 57.5%, and 23.3% of patients, respectively. Patients had a median of five prior lines of systemic therapy (range, 2-17), with 89% of patients being triple-refractory. The median duration of follow-up was 3.0 months (range, 0.7-22.1). The most common treatment-emergent adverse events (TEAEs) were fatigue (45.2%), cytokine release syndrome (CRS) (38.4%), pyrexia (35.6%), and nausea (32.9%). There were no Grade ≥3 CRS or Grade ≥3 neurotoxicity events, and no treatment discontinuation due to CRS. Grade 3 and 4 TEAEs were reported in 31 (42.5%) and 24 patients (32.9%), respectively. The most common Grade 3/4 TEAEs were hematologic (39.0%). Responses were observed at all dose levels. Amongst patients treated at the 200-800 mg dose levels, the response rate was 75% (n=18/24). The median duration of response was not reached.REGN5458 shows early, deep, and durable responses with a manageable safety profile in triple or greater-refractory patients with RRMM. This study is funded by Regeneron.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
穆立果完成签到,获得积分10
1秒前
柠一完成签到 ,获得积分10
1秒前
GOD伟完成签到,获得积分0
1秒前
秋水完成签到 ,获得积分10
2秒前
浮云完成签到,获得积分10
2秒前
李秋静完成签到,获得积分10
3秒前
东晓完成签到,获得积分10
3秒前
Crazy完成签到 ,获得积分10
3秒前
qiangxu完成签到,获得积分10
3秒前
michellewu完成签到,获得积分10
3秒前
斯通纳完成签到 ,获得积分10
3秒前
寒冷的煜祺完成签到,获得积分10
3秒前
ZHANG完成签到,获得积分10
4秒前
甜甜球完成签到,获得积分10
5秒前
宁静致远完成签到,获得积分10
6秒前
聪明小于完成签到 ,获得积分10
6秒前
学术骗子小刚完成签到,获得积分0
6秒前
热度完成签到,获得积分10
7秒前
123完成签到,获得积分10
7秒前
无相完成签到 ,获得积分10
8秒前
HP完成签到,获得积分10
9秒前
木头人完成签到,获得积分10
9秒前
10秒前
小太阳完成签到,获得积分10
10秒前
晓先森完成签到,获得积分10
12秒前
科研小狗完成签到 ,获得积分10
13秒前
eazin完成签到 ,获得积分10
13秒前
陈宗琴完成签到,获得积分10
15秒前
15秒前
热度发布了新的文献求助10
15秒前
风云再起完成签到,获得积分10
16秒前
RadiantYT完成签到,获得积分10
16秒前
chen完成签到,获得积分10
16秒前
张正完成签到,获得积分20
17秒前
善良书蕾完成签到,获得积分10
17秒前
苏打发布了新的文献求助10
18秒前
前进中完成签到,获得积分10
18秒前
你怎么这么可爱啊完成签到 ,获得积分10
19秒前
Luna爱科研完成签到 ,获得积分10
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968593
求助须知:如何正确求助?哪些是违规求助? 3513416
关于积分的说明 11167791
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794507
邀请新用户注册赠送积分活动 875170
科研通“疑难数据库(出版商)”最低求助积分说明 804671